Thermo Fisher Scientific Expansion in France Boosts Capabilities from Development to Commercial Manufacturing

Bourgoin Early Development Hub broadens offerings for oral solid dose formulations

WALTHAM, Mass. & BOURGOIN, France--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site, enabling that location to address customers’ workflow from early drug development through commercial manufacturing and underscoring the company’s commitment to helping clients get medicines to patients sooner.

“In the last decade, Thermo Fisher has led and advanced the field of oral solid dose development, with 126 new drug approvals supported,” said Leon Wyszkowski, president of pharma services commercial operations. “Expanding our capabilities in France is a further investment in our global oral solid network that will allow us to further forge partnerships with customers who depend on our capabilities for the development and commercial production of lifesaving drugs for their patients.”

In late 2021, the French government’s France Relance economic stimulus plan provided a grant to support the early development hub. Construction work began during the first quarter of 2022 enabling first activities to be launched in June 2022.

In addition to expanded good manufacturing practices (GMP) facilities, the early development hub includes a 430-square-meter (4,600 square feet) research and development facility for pre-clinical, non-GMP operations.

Bourgoin is a Thermo Fisher center of excellence in Europe for oral solid dose end-to-end drug product development and high potent substance handling. Capabilities there encompass all conventional oral solid dose manufacturing equipment to deliver tablets, capsules and granules, as well as specialized technologies such as compaction and compression-contained simulation and Accelerated Stability Assessment Program (ASAP) simulation.

This expansion in Bourgoin builds on the company's investments in small molecule solutions, including oral solid dose development and manufacturing services in Bend, Ore., U.S.; Greenville, N.C., U.S.; Cincinnati, OH, U.S.; Manatí, Puerto Rico; Toronto, Canada; Whitby, Canada; and Milton Park, U.K.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005195/en/